The Aurora Kinase Inhibitor MLN8237 Has Potent Anticancer Activity in CML and Ph+ ALL Models and Significantly Increases the Efficacy of Nilotinib
Steffan T. Nawrocki(University of Arizona), Jennifer S. Carew(University of Arizona), Ronan Swords(University of Miami), Francis J. Giles(National University of Ireland), Jeffrey Ecsedy(Howard Hughes Medical Institute), Kevin R. Kelly(Keck Hospital of USC), Sabrina Smith(The University of Texas at San Antonio Health Science Center), Ernest Medina(The University of Texas at San Antonio Health Science Center)
Cited by 6
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782